Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biovica International AB (publ)
  6. News
  7. Summary
    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biovica International : DiviTumTKa prognostic for long-term outcome

03/11/2021 | 05:11am EDT

Biovica, active in cancer diagnostics, today announced that the results from the breast cancer study PROMIX at Karolinska University Hospital is published in the scientific journal ESMO Open. The study showed that testing for TKa levels during early treatment is prognostic for the long-term outcome of preoperative chemotherapy.

“The study at Karolinska University Hospital is yet an example of the many notable research collaborations that Biovica has, and we are pleased to see the results being published in the well-renown ESMO Open. The results support the use of DiviTum®TKa as a blood-based alternative to the tissue-based Ki67 biomarker when assessing breast tumor cell growth. Also this is yet an evidence of DiviTum®TKa’s strong prognostic capabilities,” said Anders Rylander, CEO of Biovica.

The study, PROMIX (NCT00957125) is aimed to predict response of preoperative treatment in patients with early breast cancer. DiviTum®TKa was incorporated in the study as a blood-based biomarker to predict patient outcome measured as treatment response and risk of recurrence after performing surgery to remove the tumor. The aim was further to validate the TKa biomarker against another biomarker, Ki67, known also to measure the tumor growth activity, but within a tissue-testing workflow more cumbersome than the blood-based DiviTum®TKa analysis. Samples from 125 breast cancer patients were collected pre-treatment, during therapy and at surgery.

The results demonstrate that serial measurements of TKa during the preoperative chemotherapy treatment period provides long-term prognostic information on Event Free Survival (EFS) and Overall Survival (OS). A high increase in TKa after two cycles of chemotherapy resulted in improved EFS and OS. Hence, testing for TKa levels during early treatment will predict the long-term outcome of chemotherapy provided before surgery. The study also showed a significant interaction between the prognostic value of TKa and Ki67. This supports the use of DiviTum®TKa as a blood-based alternative to the tissue-based Ki67 biomarker when assessing breast tumor cell growth.

Link to study publication: Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer - ESMO Open

© Modular Finance, source Nordic Press Releases

All news about BIOVICA INTERNATIONAL AB (PUBL)
07/30BIOVICA INTERNATIONAL : Notice of annual general meeting in Biovica Internationa..
AQ
06/30BIOVICA INTERNATIONAL AB : – Annual report for the financial year 2020/202..
AQ
06/17BIOVICA INTERNATIONAL : Year-end Report February-April 2020/2021
AQ
06/17Biovica International AB Publ Reports Earnings Results for the Fourth Quarter..
CI
06/11BIOVICA INTERNATIONAL : - Premium potential
AQ
05/22BIOVICA INTERNATIONAL : Capital Markets Day invitation June 9
AQ
05/20BIOVICA INTERNATIONAL : DiviTumTKa shows strong capabilities in malignant melano..
AQ
05/20Biovica’S Divitumtka Shows Strong Capabilities in Malignant Melanoma
CI
04/29BIOVICA INTERNATIONAL : strengthens the management team
AQ
04/29Biovica Announces Management Appointments
CI
More news
Financials
Sales 2022 39,0 M 4,54 M 4,54 M
Net income 2022 -28,0 M -3,26 M -3,26 M
Net cash 2022 90,0 M 10,5 M 10,5 M
P/E ratio 2022 -61,0x
Yield 2022 -
Capitalization 1 716 M 200 M 200 M
EV / Sales 2022 41,7x
EV / Sales 2023 24,4x
Nbr of Employees 20
Free-Float 41,9%
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Last Close Price 60,40 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Anders Rylander Chief Executive Officer & Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Lars Erik Holmqvist Chairman
Mattias Bergqvist Director-Clinical Development
Otti Bengtsson Gref Director-Research & Development
Sector and Competitors